Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 1475 entries
View as:

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04175925 Org: User:
Start: 11/15/19 End: 07/13/21 Due: 07/13/22

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

Phase: N/A Priority: Normal
NCT ID: NCT04572893 Org: User:
Start: 08/04/20 End: 02/22/24 Due: 02/22/25

Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01514864 Org: User:
Start: 05/31/12 End: 07/23/14 Due: 07/23/15

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03071133 Org: User:
Start: 01/01/18 End: 01/08/19 Due: 01/08/20

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03661320 Org: User:
Start: 11/06/18 End: 12/30/27 Due: 12/30/28

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01359657 Org: User:
Start: 09/30/11 End: 03/31/16 Due: 03/31/17

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

Phase: N/A Priority: Normal
NCT ID: NCT03447990 Org: User:
Start: 02/06/18 End: 10/24/19 Due: 10/24/20

A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept

Phase: N/A Priority: Normal
NCT ID: NCT03188081 Org: User:
Start: 08/02/17 End: 08/24/20 Due: 08/24/21

Multiple Dose Japanese Bridging Study

Phase: N/A Priority: Normal
NCT ID: NCT01057030 Org: User:
Start: 03/31/10 End: 06/30/10 Due: 06/30/11

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05760937 Org: User:
Start: 03/10/23 End: 11/27/23 Due: 11/27/24

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01460160 Org: User:
Start: 04/13/12 End: 06/01/21 Due: 06/01/22

A Phase II Dose Response Study in Japan in Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT01022801 Org: User:
Start: 08/31/03 End: 03/31/05 Due: 03/31/06

Korean Post-marketing Surveillance for Reyataz®

Phase: N/A Priority: Normal
NCT ID: NCT01450605 Org: User:
Start: 12/31/11 End: 03/31/16 Due: 03/31/17

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT06396039 Org: User:
Start: 05/15/24 End: 03/30/29 Due: 03/30/30

A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT05405543 Org: User:
Start: 07/12/22 End: 12/09/22 Due: 12/09/23

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Phase: N/A Priority: Normal
NCT ID: NCT04146324 Org: User:
Start: 12/12/19 End: 05/31/24 Due: 05/31/25

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04895709 Org: User:
Start: 05/27/21 End: 12/31/26 Due: 12/31/27

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Phase: N/A Priority: Normal
NCT ID: NCT05582395 Org: User:
Start: 12/14/22 End: 06/29/29 Due: 06/29/30

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00872976 Org: User:
Start: 05/31/09 End: 12/31/11 Due: 12/31/12

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01836705 Org: User:
Start: 05/31/13 End: 05/31/14 Due: 05/31/15

Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06577259 Org: User:
Start: 09/03/24 End: 02/19/25 Due: 02/19/26

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00452530 Org: User:
Start: 06/30/07 End: 01/31/09 Due: 01/31/10

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03834662 Org: User:
Start: 01/07/19 End: 02/19/20 Due: 02/19/21

Multiple Ascending Dose (MDX1105-01)

Phase: N/A Priority: Normal
NCT ID: NCT00729664 Org: User:
Start: 02/28/09 End: 07/31/15 Due: 07/31/16

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Phase: N/A Priority: Normal
NCT ID: NCT00162123 Org: User:
Start: 05/31/06 End: 04/30/14 Due: 04/30/15